Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1403775,total plasma,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4261,DB00861,Diflunisal
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],181,4262,DB00861,Diflunisal
,1403775,clearance,"After i.v. administration, total plasma clearance of L-689,502 in rats decreased with increasing dose; the clearance decreased from 181 ml/min/kg at 1 mg/kg to 86 ml/min/kg at 20 mg/kg.","Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],86,4263,DB00861,Diflunisal
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],29,4264,DB00861,Diflunisal
,1403775,clearance,Similar results were observed in dogs; clearance fell from 29 ml/min/kg at 0.5 mg/kg to 17 ml/min/kg at 10 mg/kg.,"Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403775/),[ml] / [kg·min],17,4265,DB00861,Diflunisal
,314299,relative bioavailability,"3 From the AUC-method, a relative bioavailability of 0.60 was calculated.",Effect of aluminum hydroxide on diflunisal absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/314299/),,0.60,4898,DB00861,Diflunisal
,31302476,flow rate,"An UHPLC analysis was performed on a Zorbax Eclipse Plus C8 (150 mm × 3.0 mm ID × 1.8 μm particles) column with a mobile phase of acetonitrile:water:phosphoric acid (50:50:0.1, v/v) using a flow rate of 0.6 mL/min.","Determination of Ochratoxin-A in the brain microdialysates and plasma of awake, freely moving rats using ultra high performance liquid chromatography fluorescence detection method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31302476/),[ml] / [min],0.6,6275,DB00861,Diflunisal
,31302476,limit of,"The limit of detection and the limit of quantification values were found to be 0.490 ng/mL and 1.48 ng/mL for plasma; 0.0900 ng/mL and 0.270 ng/mL for microdialysate samples, respectively.","Determination of Ochratoxin-A in the brain microdialysates and plasma of awake, freely moving rats using ultra high performance liquid chromatography fluorescence detection method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31302476/),[ng] / [ml],0.490,6276,DB00861,Diflunisal
,31302476,limit of,"The limit of detection and the limit of quantification values were found to be 0.490 ng/mL and 1.48 ng/mL for plasma; 0.0900 ng/mL and 0.270 ng/mL for microdialysate samples, respectively.","Determination of Ochratoxin-A in the brain microdialysates and plasma of awake, freely moving rats using ultra high performance liquid chromatography fluorescence detection method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31302476/),[ng] / [ml],0.0900,6277,DB00861,Diflunisal
,31302476,limit of quantification,"The limit of detection and the limit of quantification values were found to be 0.490 ng/mL and 1.48 ng/mL for plasma; 0.0900 ng/mL and 0.270 ng/mL for microdialysate samples, respectively.","Determination of Ochratoxin-A in the brain microdialysates and plasma of awake, freely moving rats using ultra high performance liquid chromatography fluorescence detection method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31302476/),[ng] / [ml],1.48,6278,DB00861,Diflunisal
,31302476,limit of quantification,"The limit of detection and the limit of quantification values were found to be 0.490 ng/mL and 1.48 ng/mL for plasma; 0.0900 ng/mL and 0.270 ng/mL for microdialysate samples, respectively.","Determination of Ochratoxin-A in the brain microdialysates and plasma of awake, freely moving rats using ultra high performance liquid chromatography fluorescence detection method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31302476/),[ng] / [ml],0.270,6279,DB00861,Diflunisal
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.31,9164,DB00861,Diflunisal
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.28,9165,DB00861,Diflunisal
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.2,9166,DB00861,Diflunisal
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],10.5,9167,DB00861,Diflunisal
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],3.3,9168,DB00861,Diflunisal
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],7.8,9169,DB00861,Diflunisal
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9170,DB00861,Diflunisal
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9171,DB00861,Diflunisal
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9172,DB00861,Diflunisal
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9173,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9174,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,19,9175,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,63,9176,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,109,9177,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9178,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,13,9179,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,49,9180,DB00861,Diflunisal
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,122,9181,DB00861,Diflunisal
,1862662,plasma clearance,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),[ml] / [kg·min],7.8,18103,DB00861,Diflunisal
,1862662,plasma clearance,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),[ml] / [kg·min],6.0,18104,DB00861,Diflunisal
,1862662,plasma clearance,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),[ml] / [kg·min],3.2,18105,DB00861,Diflunisal
,1862662,plasma clearance,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),[ml] / [kg·min],2.2,18106,DB00861,Diflunisal
,1862662,apparent terminal plasma half-life,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),h,2.1,18107,DB00861,Diflunisal
,1862662,apparent terminal plasma half-life,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),h,2.6,18108,DB00861,Diflunisal
,1862662,apparent terminal plasma half-life,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),h,3.4,18109,DB00861,Diflunisal
,1862662,apparent terminal plasma half-life,"4. Blockage of excretion routes by ligation of the ureters, bile duct, and both ureters and bile duct, decreased plasma clearance of the acyl glucuronide from 7.8 ml/min per kg to 6.0, 3.2 and 2.2 ml/min per kg respectively, and increased the apparent terminal plasma half-life of DF from 2.1 h to 2.6, 3.4 and 6.3 h, respectively.",Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1862662/),h,6.3,18110,DB00861,Diflunisal
exceeding,17107884,binding stoichiometry,"In the 250 mg bid group, 12 h after the 13th oral dose, the diflunisal serum concentration of 146 +/- 39 microM was sufficient to afford a TTR binding stoichiometry exceeding 0.95 +/- 0.13 ( approximately 1.75 corrected).",Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17107884/),,0.95,46333,DB00861,Diflunisal
,11939069,flow rate,The flow rate was 1.0 ml.min-1.,[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),[ml] / [min],1.0,56271,DB00861,Diflunisal
,11939069,detection limit,"ml-1, with the lowest detection limit 0.02 microgram.",[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),μg,0.02,56272,DB00861,Diflunisal
,11939069,S/N,ml-1 (S/N = 2).,[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),,2,56273,DB00861,Diflunisal
,11939069,extraction,"The extraction and method recoveries were 91.65% and 97.25% respectively, while the RSD for the within-day and between-day precision were all less than 10%.",[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),%,91.65,56274,DB00861,Diflunisal
,11939069,recoveries,"The extraction and method recoveries were 91.65% and 97.25% respectively, while the RSD for the within-day and between-day precision were all less than 10%.",[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),%,97.25,56275,DB00861,Diflunisal
,11939069,T1/2 alpha,"The T1/2 alpha and T1/2 beta were 1.40 h and 17.85 h, respectively.",[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),h,1.40,56276,DB00861,Diflunisal
,11939069,T1/2 beta,"The T1/2 alpha and T1/2 beta were 1.40 h and 17.85 h, respectively.",[Determination of diflunisal in plasma by RP-HPLC after solid-liquid extraction]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11939069/),h,17.85,56277,DB00861,Diflunisal
,3556822,plasma elimination half-life,The plasma elimination half-life was calculated to be 10.2 hr over the period of 1 to 8 hr postadministration.,Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3556822/),h,10.2,61504,DB00861,Diflunisal
greater,3556822,Plasma protein binding,Plasma protein binding averaged greater than 99% over a concentration range of 62.5 to 250 micrograms/ml.,Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3556822/),%,99,61505,DB00861,Diflunisal
,3556822,Urinary excretion,"Urinary excretion of diflunisal and metabolites averaged 66.5% of the dosage over the first 4 days postadministration, compared with 0.8% in the feces.",Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3556822/),%,66.5,61506,DB00861,Diflunisal
,3556822,Urinary excretion,"Urinary excretion of diflunisal and metabolites averaged 66.5% of the dosage over the first 4 days postadministration, compared with 0.8% in the feces.",Evaluation of the teratogenicity and pharmacokinetics of diflunisal in cynomolgus monkeys. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3556822/),%,0.8,61507,DB00861,Diflunisal
,8886486,peak concentrations,"2. After administration of DF (1 mg/0.5 mL buffer, pH 7) into the bladder of anaesthetized bile-exteriorized rats, DF appeared rapidly in plasma, achieving peak concentrations of 7 micrograms/mL at 1 h.",Vesico-hepato-renal cycling of acidic drugs via their reactive acyl glucuronide metabolites? Studies with diflunisal in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886486/),[μg] / [ml],7,85227,DB00861,Diflunisal
,3402529,Total urinary excretion (0-24 h),Total urinary excretion (0-24 h) was 36.6 +/- 16.4% of the 250 mg dose.,Biliary excretion of diflunisal conjugates in patients with T-tube drainage. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402529/),%,36.6,86054,DB00861,Diflunisal
,1606992,plasma clearance,The plasma clearance of total (bound + unbound) diflunisal was 10.2 ml.,Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606992/),ml,10.2,89954,DB00861,Diflunisal
,1606992,percentage of unbound,The plasma protein binding of diflunisal was significantly reduced in cirrhosis; the percentage of unbound diflunisal in plasma was 0.089 in the controls and 0.147 in the patients with cirrhosis.,Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606992/),,0.089,89955,DB00861,Diflunisal
,1606992,percentage of unbound,The plasma protein binding of diflunisal was significantly reduced in cirrhosis; the percentage of unbound diflunisal in plasma was 0.089 in the controls and 0.147 in the patients with cirrhosis.,Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606992/),,0.147,89956,DB00861,Diflunisal
,1606992,Plasma clearance,Plasma clearance of unbound diflunisal was significantly impaired in cirrhosis: 11.5 l.min-1 in control subjects vs 7.41.min-1 in cirrhotics.,Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606992/),[l] / [min],11.5,89957,DB00861,Diflunisal
,1606992,Plasma clearance,Plasma clearance of unbound diflunisal was significantly impaired in cirrhosis: 11.5 l.min-1 in control subjects vs 7.41.min-1 in cirrhotics.,Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1606992/),1/[min],7.41,89958,DB00861,Diflunisal
,7768255,steady state plasma concentration,The steady state plasma concentration of diflunisal was significantly higher during the probenecid treatment phase as compared to the control phase (104.0 vs. 63.1 micrograms.ml-1).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[μg] / [ml],104.0,90887,DB00861,Diflunisal
,7768255,steady state plasma concentration,The steady state plasma concentration of diflunisal was significantly higher during the probenecid treatment phase as compared to the control phase (104.0 vs. 63.1 micrograms.ml-1).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[μg] / [ml],63.1,90888,DB00861,Diflunisal
,7768255,plasma clearance,This was the result of a significant decrease in the plasma clearance of diflunisal from 5.8 (control) to 3.4 ml.min-1 (probenecid co-administration).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[ml] / [min],5.8,90889,DB00861,Diflunisal
,7768255,plasma clearance,This was the result of a significant decrease in the plasma clearance of diflunisal from 5.8 (control) to 3.4 ml.min-1 (probenecid co-administration).,Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768255/),[ml] / [min],3.4,90890,DB00861,Diflunisal
,2591467,renal clearance,High dose diflunisal (1500 mg/day) decreased the renal clearance of indomethacin from 21.9 to 1.8 ml/min (92%) and reduced the renal excretion of both unchanged (63%) and conjugated (82%) indomethacin.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[ml] / [min],21.9,121315,DB00861,Diflunisal
,2591467,renal clearance,High dose diflunisal (1500 mg/day) decreased the renal clearance of indomethacin from 21.9 to 1.8 ml/min (92%) and reduced the renal excretion of both unchanged (63%) and conjugated (82%) indomethacin.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[ml] / [min],1.8,121316,DB00861,Diflunisal
,2591467,apparent total body clearance,"The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[l] / [h·kg],0.12,121317,DB00861,Diflunisal
,2591467,apparent volume of distribution,"The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[l] / [kg],0.98,121318,DB00861,Diflunisal
,2591467,volume of distribution at steady state,"The apparent total body clearance (0.12 l/h/kg), apparent volume of distribution (0.98 l/kg), and volume of distribution at steady state (0.80 l/kg) were decreased by 47%, 35% and 30%.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[l] / [kg],0.80,121319,DB00861,Diflunisal
,2591467,maximum plasma concentration,"The maximum plasma concentration (2.4 micrograms/ml) and total area under the curve (13.0 micrograms x h/ml) were increased by 40% and 119%, respectively.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[μg] / [ml],2.4,121320,DB00861,Diflunisal
,2591467,total area under the curve,"The maximum plasma concentration (2.4 micrograms/ml) and total area under the curve (13.0 micrograms x h/ml) were increased by 40% and 119%, respectively.","Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),[h·μg] / [ml],13.0,121321,DB00861,Diflunisal
,2591467,terminal elimination half-life,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,5.7,121322,DB00861,Diflunisal
,2591467,mean residence time,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,6.7,121323,DB00861,Diflunisal
,2591467,mean residence time,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,7.0,121324,DB00861,Diflunisal
,2591467,mean residence time,The terminal elimination half-life (5.7 h) and mean residence time (6.7 h) were slightly prolonged (7.0 h and 8.8 h) in the presence of diflunisal.,"Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591467/),h,8.8,121325,DB00861,Diflunisal
,1763527,urinary recoveries,"In intact Wistar rats, urinary recoveries of the metabolites were 15%, 13%, 23% and 5%, respectively.",Absence of phenolic glucuronidation and enhanced hydroxylation of diflunisal in the homozygous Gunn rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763527/),%,15,124174,DB00861,Diflunisal
,1763527,urinary recoveries,"In intact Wistar rats, urinary recoveries of the metabolites were 15%, 13%, 23% and 5%, respectively.",Absence of phenolic glucuronidation and enhanced hydroxylation of diflunisal in the homozygous Gunn rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763527/),%,13,124175,DB00861,Diflunisal
,1763527,urinary recoveries,"In intact Wistar rats, urinary recoveries of the metabolites were 15%, 13%, 23% and 5%, respectively.",Absence of phenolic glucuronidation and enhanced hydroxylation of diflunisal in the homozygous Gunn rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763527/),%,23,124176,DB00861,Diflunisal
,1763527,urinary recoveries,"In intact Wistar rats, urinary recoveries of the metabolites were 15%, 13%, 23% and 5%, respectively.",Absence of phenolic glucuronidation and enhanced hydroxylation of diflunisal in the homozygous Gunn rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763527/),%,5,124177,DB00861,Diflunisal
,7426277,renal clearance,"4 With alkaline diuresis there was a significant increase in the mean renal clearance of diflunisal from 0.27 to 0.46 ml/min, but there was no significant correlation between the renal clearance of diflunisal and urine flow or pH.",Failure of alkaline diuresis to enhance diflunisal elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426277/),[ml] / [min],0.27,148251,DB00861,Diflunisal
,7426277,renal clearance,"4 With alkaline diuresis there was a significant increase in the mean renal clearance of diflunisal from 0.27 to 0.46 ml/min, but there was no significant correlation between the renal clearance of diflunisal and urine flow or pH.",Failure of alkaline diuresis to enhance diflunisal elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426277/),[ml] / [min],0.46,148252,DB00861,Diflunisal
,7426277,overall mean renal clearance,"However, there was a significant increase in the overall mean renal clearance of diflunisal from 0.22 ml/min over the period 0-24 h to 0.73 ml/min from 48-72 h.",Failure of alkaline diuresis to enhance diflunisal elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426277/),[ml] / [min],0.22,148253,DB00861,Diflunisal
,7426277,overall mean renal clearance,"However, there was a significant increase in the overall mean renal clearance of diflunisal from 0.22 ml/min over the period 0-24 h to 0.73 ml/min from 48-72 h.",Failure of alkaline diuresis to enhance diflunisal elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426277/),[ml] / [min],0.73,148254,DB00861,Diflunisal
,2328191,plasma clearance,"2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/- 1.2 and 4.2 +/- 0.7 ml min-1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/- 3.1 and 9.9 +/- 2.0 ml min-1 for the 250 and 500 mg single doses, respectively).",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),[ml] / [min],5.2,151586,DB00861,Diflunisal
,2328191,plasma clearance,"2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/- 1.2 and 4.2 +/- 0.7 ml min-1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/- 3.1 and 9.9 +/- 2.0 ml min-1 for the 250 and 500 mg single doses, respectively).",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),[ml] / [min],4.2,151587,DB00861,Diflunisal
,2328191,plasma clearance,"2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/- 1.2 and 4.2 +/- 0.7 ml min-1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/- 3.1 and 9.9 +/- 2.0 ml min-1 for the 250 and 500 mg single doses, respectively).",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),[ml] / [min],11.4,151588,DB00861,Diflunisal
,2328191,plasma clearance,"2. The plasma clearance of diflunisal was lowered significantly after multiple dose administration (5.2 +/- 1.2 and 4.2 +/- 0.7 ml min-1 for the 250 and 500 mg twice daily regimens, respectively) as compared with single dose administration 11.4 +/- 3.1 and 9.9 +/- 2.0 ml min-1 for the 250 and 500 mg single doses, respectively).",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),[ml] / [min],9.9,151589,DB00861,Diflunisal
,2328191,urinary recovery,"4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/- 2.8 and 9.1 +/- 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/- 3.1 and 15.9 +/- 3.6% following the 250 and 500 mg twice daily regimens.",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),%,6.1,151590,DB00861,Diflunisal
,2328191,urinary recovery,"4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/- 2.8 and 9.1 +/- 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/- 3.1 and 15.9 +/- 3.6% following the 250 and 500 mg twice daily regimens.",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),%,9.1,151591,DB00861,Diflunisal
,2328191,urinary recovery,"4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/- 2.8 and 9.1 +/- 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/- 3.1 and 15.9 +/- 3.6% following the 250 and 500 mg twice daily regimens.",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),%,10.9,151592,DB00861,Diflunisal
,2328191,urinary recovery,"4. The urinary recovery of diflunisal sulphate increased as a function of dose: 6.1 +/- 2.8 and 9.1 +/- 3.5% following the 250 and 500 mg single dose, respectively, and 10.9 +/- 3.1 and 15.9 +/- 3.6% following the 250 and 500 mg twice daily regimens.",The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328191/),%,15.9,151593,DB00861,Diflunisal
,4041343,peak plasma concentration,"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ng] / [ml],387,151725,DB00861,Diflunisal
,4041343,peak plasma concentration,"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ng] / [ml],241,151726,DB00861,Diflunisal
,4041343,total area under the plasma concentration-time curve (AUC),"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],5536,151727,DB00861,Diflunisal
,4041343,total area under the plasma concentration-time curve (AUC),"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],4643,151728,DB00861,Diflunisal
,4041343,AUC,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],4771,151729,DB00861,Diflunisal
,4041343,AUC,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],8116,151730,DB00861,Diflunisal
,4041343,elimination half-life,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),h,10.0,151731,DB00861,Diflunisal
,4041343,elimination half-life,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),h,13.0,151732,DB00861,Diflunisal
,4041343,Renal clearance,Renal clearance for oxazepam glucuronide was significantly reduced from 74 +/- 2 ml min-1 to 46 +/- 3 ml min-1.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ml] / [min],74,151733,DB00861,Diflunisal
,4041343,Renal clearance,Renal clearance for oxazepam glucuronide was significantly reduced from 74 +/- 2 ml min-1 to 46 +/- 3 ml min-1.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ml] / [min],46,151734,DB00861,Diflunisal
,2609014,Maximum concentrations,"Maximum concentrations of the D- and P-adducts were achieved within one day of cessation of dosing, and were 35 +/- SE 1 and 17 +/- SE 1 ng/mg protein respectively.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),[ng] / [mg],35,167660,DB00861,Diflunisal
,2609014,Maximum concentrations,"Maximum concentrations of the D- and P-adducts were achieved within one day of cessation of dosing, and were 35 +/- SE 1 and 17 +/- SE 1 ng/mg protein respectively.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),[ng] / [mg],17,167661,DB00861,Diflunisal
,2609014,terminal half-life,"The D-protein adduct was eliminated from plasma in a biphasic manner, with a terminal half-life of 10.0 +/- SE 0.9 days.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),d,10.0,167662,DB00861,Diflunisal
,2609014,half-life,"In contrast, elimination of the P-protein adduct was monophasic with a half-life of 13.5 +/- SE 0.3 days.",Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609014/),d,13.5,167663,DB00861,Diflunisal
greater,2547464,time to reach peak plasma concentration (tmax,"Sodium bicarbonate given together and 30 min after diflunisal tablets significantly (p less than 0.05) shortened the time to reach peak plasma concentration (tmax greater than 15 per cent), raised maximum plasma concentration slightly (Cmax 6 per cent) and increased the area under the plasma concentration-time curve (AUC greater than 8 per cent).",Buffering the stomach content enhances the absorption of diflunisal in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),%,15,171847,DB00861,Diflunisal
greater,2547464,area under the plasma concentration-time curve (AUC,"Sodium bicarbonate given together and 30 min after diflunisal tablets significantly (p less than 0.05) shortened the time to reach peak plasma concentration (tmax greater than 15 per cent), raised maximum plasma concentration slightly (Cmax 6 per cent) and increased the area under the plasma concentration-time curve (AUC greater than 8 per cent).",Buffering the stomach content enhances the absorption of diflunisal in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),-1,8,171848,DB00861,Diflunisal
,2547464,terminal half-life,"In one volunteer, after intravenous administration diflunisal plasma concentrations declined in a triphasic manner with a terminal half-life of 12.8 h.",Buffering the stomach content enhances the absorption of diflunisal in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),h,12.8,171849,DB00861,Diflunisal
,2547464,volume of distribution,The volume of distribution was approximately 10 per cent of body weight.,Buffering the stomach content enhances the absorption of diflunisal in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),%,10,171850,DB00861,Diflunisal
,2547464,absolute bioavailability,"Based on the ratio of AUC after equivalent i.v. and oral diflunisal doses, the absolute bioavailability was 89.5 per cent.",Buffering the stomach content enhances the absorption of diflunisal in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2547464/),%,89.5,171851,DB00861,Diflunisal
,2338115,plasma clearance,The plasma clearance of diflunisal was significantly higher in men (0.169 ml.min-1.kg-1) and in women on OCS (0.165 ml.min-1.kg-1) as compared to control women (0.108 ml.min-1.kg-1).,Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338115/),[ml] / [kg·min],0.169,186971,DB00861,Diflunisal
,2338115,plasma clearance,The plasma clearance of diflunisal was significantly higher in men (0.169 ml.min-1.kg-1) and in women on OCS (0.165 ml.min-1.kg-1) as compared to control women (0.108 ml.min-1.kg-1).,Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338115/),[ml] / [kg·min],0.165,186972,DB00861,Diflunisal
,2338115,plasma clearance,The plasma clearance of diflunisal was significantly higher in men (0.169 ml.min-1.kg-1) and in women on OCS (0.165 ml.min-1.kg-1) as compared to control women (0.108 ml.min-1.kg-1).,Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338115/),[ml] / [kg·min],0.108,186973,DB00861,Diflunisal
,2338115,partial metabolic clearance,"Statistically significant increases, however, were only observed for the partial metabolic clearance of diflunisal by phenolic glucuronidation between men and women (2.91 vs.",Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338115/),,2.91,186974,DB00861,Diflunisal
,2338115,partial clearance,"1.85 ml.min-1 respectively), and for the partial clearance by acyl glucuronidation between OCS users and control women (4.81 vs. 3.01 ml.min-1 respectively).",Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338115/),[ml] / [min],4.81,186975,DB00861,Diflunisal
,2338115,partial clearance,"1.85 ml.min-1 respectively), and for the partial clearance by acyl glucuronidation between OCS users and control women (4.81 vs. 3.01 ml.min-1 respectively).",Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338115/),[ml] / [min],3.01,186976,DB00861,Diflunisal
,3203058,Total urinary recovery,2. Total urinary recovery ranged from 78.9 +/- 11.9% to 91.5 +/- 18.7% of the administered dose.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),%,78.9,191782,DB00861,Diflunisal
,3203058,Total urinary recovery,2. Total urinary recovery ranged from 78.9 +/- 11.9% to 91.5 +/- 18.7% of the administered dose.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),%,91.5,191783,DB00861,Diflunisal
,3203058,Urinary recovery,Urinary recovery (normalized for total urinary recovery) of diflunisal sulphate (DS) significantly increased with dose from 9.3 +/- 3.7% to 18.1 +/- 4.8%.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),%,9.3,191784,DB00861,Diflunisal
,3203058,Urinary recovery,Urinary recovery (normalized for total urinary recovery) of diflunisal sulphate (DS) significantly increased with dose from 9.3 +/- 3.7% to 18.1 +/- 4.8%.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),%,18.1,191785,DB00861,Diflunisal
,3203058,Normalized urinary recovery,3. Normalized urinary recovery for diflunisal phenolic glucuronide (DPG) was unaffected by dose (range: 30.6 +/- 3.8% to 40.6 +/- 6.6%).,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),%,30.6,191786,DB00861,Diflunisal
,3203058,Normalized urinary recovery,3. Normalized urinary recovery for diflunisal phenolic glucuronide (DPG) was unaffected by dose (range: 30.6 +/- 3.8% to 40.6 +/- 6.6%).,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),%,40.6,191787,DB00861,Diflunisal
,3203058,Normalized urinary recovery,Normalized urinary recovery for the acyl glucuronide (DAG) significantly decreased from 52.3 +/- 4.6% to 40.2 +/- 3.4% as the dose increased.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),,52,191788,DB00861,Diflunisal
,3203058,Normalized urinary recovery,Normalized urinary recovery for the acyl glucuronide (DAG) significantly decreased from 52.3 +/- 4.6% to 40.2 +/- 3.4% as the dose increased.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),,40,191789,DB00861,Diflunisal
,3203058,Total plasma clearance,4. Total plasma clearance of diflunisal significantly decreased from 14.4 +/- 1.4 ml min-1 to 8.7 +/- 1.4 ml min-1 as the dose increased from 100 mg to 750 mg.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),[ml] / [min],14.4,191790,DB00861,Diflunisal
,3203058,Total plasma clearance,4. Total plasma clearance of diflunisal significantly decreased from 14.4 +/- 1.4 ml min-1 to 8.7 +/- 1.4 ml min-1 as the dose increased from 100 mg to 750 mg.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),[ml] / [min],8.7,191791,DB00861,Diflunisal
,3203058,total plasma clearance,A further increase in dose to 1000 mg resulted in an unexplained increase in total plasma clearance to 10.3 +/- 1.8 ml min-1.,Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203058/),[ml] / [min],10.3,191792,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,12.2,209511,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,23.8,209512,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,0.4,209513,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,10.3,209514,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,5.6,209515,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,15.2,209516,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,11.3,209517,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,41.6,209518,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,1.0,209519,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,2.9,209520,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,1.1,209521,DB00861,Diflunisal
,2612067,recoveries,"3. In bile-exteriorized animals, recoveries of DPG, DAG and DS in bile were 12.2%, 23.8%, 0.4%, respectively, and in urine, 10.3%, 5.6% and 15.2%, respectively, at the 10 mg/kg dose; and in bile, 11.3%, 41.6% and 1.0% respectively, and urine 2.9%, 1.1% and 17.0%, respectively, at the 100 mg/kg dose.","Elimination of diflunisal as its acyl glucuronide, phenolic glucuronide and sulfate conjugates in bile-exteriorized and intact rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612067/),%,17.0,209522,DB00861,Diflunisal
,6663474,area under the plasma concentration-time curves (AUC,There was a disproportionate increase in the area under the plasma concentration-time curves (AUC 750 mg/AUC 250 mg was 3.84 for subject A and 4.22 for subject B) and a reduction in plasma clearance after the 750-mg dose of diflunisal.,High-performance liquid chromatographic analysis of diflunisal in plasma and urine: application to pharmacokinetic studies in two normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6663474/),,3.84,227186,DB00861,Diflunisal
,6663474,area under the plasma concentration-time curves (AUC,There was a disproportionate increase in the area under the plasma concentration-time curves (AUC 750 mg/AUC 250 mg was 3.84 for subject A and 4.22 for subject B) and a reduction in plasma clearance after the 750-mg dose of diflunisal.,High-performance liquid chromatographic analysis of diflunisal in plasma and urine: application to pharmacokinetic studies in two normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6663474/),,4.22,227187,DB00861,Diflunisal
,2219966,Total plasma clearance,4. Total plasma clearance of DF decreased from 1.01 to 0.68 ml/min per kg following bile duct ligation.,Effects of blockage of urine and/or bile flow on diflunisal conjugation and disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2219966/),[ml] / [kg·min],1.01,229423,DB00861,Diflunisal
,2219966,Total plasma clearance,4. Total plasma clearance of DF decreased from 1.01 to 0.68 ml/min per kg following bile duct ligation.,Effects of blockage of urine and/or bile flow on diflunisal conjugation and disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2219966/),[ml] / [kg·min],0.68,229424,DB00861,Diflunisal
,2219966,total plasma clearance,"5. In rats with blockage of both urinary and biliary excretion routes, total plasma clearance of DF decreased to 0.59 ml/min per kg.",Effects of blockage of urine and/or bile flow on diflunisal conjugation and disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2219966/),[ml] / [kg·min],0.59,229425,DB00861,Diflunisal
,3841206,steady-state peak plasma concentrations,The mean (+/- SD) steady-state peak plasma concentrations were significantly greater after once-daily dosing (186 +/- 25 micrograms/ml vs 150 +/- 37 micrograms/ml; p less than 0.01).,Steady-state disposition of diflunisal: once- versus twice-daily administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[μg] / [ml],186,238086,DB00861,Diflunisal
,3841206,steady-state peak plasma concentrations,The mean (+/- SD) steady-state peak plasma concentrations were significantly greater after once-daily dosing (186 +/- 25 micrograms/ml vs 150 +/- 37 micrograms/ml; p less than 0.01).,Steady-state disposition of diflunisal: once- versus twice-daily administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[μg] / [ml],150,238087,DB00861,Diflunisal
,3841206,time to peak concentration,The time to peak concentration was also longer after the single-dose regimen (2.5 +/- 0.8 vs 1.9 +/- 0.9 hr; p less than 0.05).,Steady-state disposition of diflunisal: once- versus twice-daily administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),h,2.5,238088,DB00861,Diflunisal
,3841206,time to peak concentration,The time to peak concentration was also longer after the single-dose regimen (2.5 +/- 0.8 vs 1.9 +/- 0.9 hr; p less than 0.05).,Steady-state disposition of diflunisal: once- versus twice-daily administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),h,1.9,238089,DB00861,Diflunisal
,3841206,area under the plasma concentration-time curve at steady state,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[h·μg] / [ml],2839,238090,DB00861,Diflunisal
,3841206,area under the plasma concentration-time curve at steady state,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[h·μg] / [ml],2782,238091,DB00861,Diflunisal
,3841206,steady-state plasma concentrations,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[μg] / [ml],118,238092,DB00861,Diflunisal
,3841206,steady-state plasma concentrations,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[μg] / [ml],116,238093,DB00861,Diflunisal
,3841206,trough plasma concentration,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[μg] / [ml],85,238094,DB00861,Diflunisal
,3841206,trough plasma concentration,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),[μg] / [ml],92,238095,DB00861,Diflunisal
,3841206,urinary excretion,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),mg,776,238096,DB00861,Diflunisal
,3841206,urinary excretion,"The regimens were similar with respect to the mean 24-hour area under the plasma concentration-time curve at steady state (2839 +/- 612 vs 2782 +/- 778 micrograms.hr.ml-1), steady-state plasma concentrations (118 +/- 25 vs 116 +/- 32 micrograms/ml), trough plasma concentration (85 +/- 27 vs 92 +/- 28 micrograms/ml) as well as 24-hour urinary excretion (776 +/- 79 vs 771 +/- 89 mg) of diflunisal.",Steady-state disposition of diflunisal: once- versus twice-daily administration. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3841206/),mg,771,238097,DB00861,Diflunisal
,2861991,excretion,"Within 26 hr after iv administration of diflunisal (10 mg/kg) to rats, excretion was as follows: 42.2% of the dose, bile; 2.3%, unchanged drug; 27.8%, ester glucuronide; and 12.1%, ether glucuronide.",Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861991/),,2,252088,DB00861,Diflunisal
,2861991,excretion,"Within 26 hr after iv administration of diflunisal (10 mg/kg) to rats, excretion was as follows: 42.2% of the dose, bile; 2.3%, unchanged drug; 27.8%, ester glucuronide; and 12.1%, ether glucuronide.",Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861991/),,27,252089,DB00861,Diflunisal
,2861991,excretion,"Within 26 hr after iv administration of diflunisal (10 mg/kg) to rats, excretion was as follows: 42.2% of the dose, bile; 2.3%, unchanged drug; 27.8%, ester glucuronide; and 12.1%, ether glucuronide.",Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861991/),,12,252090,DB00861,Diflunisal
,2670397,elimination half-life,"Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid.",Diclofenac sodium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2670397/),h,1.5,252500,DB00861,Diflunisal
,2029803,maximum plasma diflunisal concentration,"Ten pharmacokinetic profiles obtained from 8 patients showed a maximum plasma diflunisal concentration of 62.0 +/- 26.5 mg/L after 2.76 +/- 1.87 hours, and an area under the plasma concentration-time curve (AUC) of 678.3 +/- 362.3 mg/L.h.",Pharmacokinetics of diflunisal in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029803/),[mg] / [l],62.0,256332,DB00861,Diflunisal
,2029803,area under the plasma concentration-time curve (AUC),"Ten pharmacokinetic profiles obtained from 8 patients showed a maximum plasma diflunisal concentration of 62.0 +/- 26.5 mg/L after 2.76 +/- 1.87 hours, and an area under the plasma concentration-time curve (AUC) of 678.3 +/- 362.3 mg/L.h.",Pharmacokinetics of diflunisal in patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029803/),[mg] / [h·l],678.3,256333,DB00861,Diflunisal
,2029803,biliary elimination,Analysis of biliary secretion of diflunisal in 4 patients suggested a biliary elimination and subsequent enterohepatic circulation ranging between 2.4 and 15.1%.,Pharmacokinetics of diflunisal in patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029803/),%,2.4,256334,DB00861,Diflunisal
